이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Autobio Diagnostics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zeng Li Yang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Does Autobio Diagnostics (SHSE:603658) Have A Healthy Balance Sheet?

May 21

Autobio Diagnostics Co., Ltd.'s (SHSE:603658) 27% Price Boost Is Out Of Tune With Earnings

Feb 27

CEO

Zeng Li Yang (56 yo)

no data

테뉴어

CN¥722,500

보상

Mr. Zeng Li Yang served as Deputy General Manager at Autobio Diagnostics Co., Ltd. and has been its Supervisors Director since 2003. Mr. Yang has been Vice president at National Health Industry Enterprise...

Autobio Diagnostics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Autobio Diagnostics Co., Ltd., Annual General Meeting, May 09, 2024

Less than half of directors are independent

Recent updates

Autobio Diagnostics Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024

Does Autobio Diagnostics (SHSE:603658) Have A Healthy Balance Sheet?

Autobio Diagnostics Co., Ltd., Annual General Meeting, May 09, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Autobio Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

Autobio Diagnostics Co., Ltd.'s (SHSE:603658) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 21%

Autobio Diagnostics Co., Ltd. (SHSE:603658) announces an Equity Buyback for CNY 500 million worth of its shares.

Autobio Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 14% to CN¥63.18

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Autobio Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Price target decreased by 12% to CN¥73.65

Price target decreased by 10% to CN¥74.78

Full year 2022 earnings released: EPS: CN¥2.00 (vs CN¥1.66 in FY 2021)

Price target increased to CN¥82.06

Less than half of directors are independent

Price target increased to CN¥80.64

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from S&P Global BMI Index

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from S&P Global BMI Index

Autobio Diagnostics Co., Ltd.(XSSC:603658) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥61.15

First quarter 2022 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥71.72

Third quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.43 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Mobidiag Oy from Autobio Diagnostics Co., Ltd. (SHSE:603658) and others for an enterprise value of approximately $810 million

First quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.22 in 1Q 2020)

New 90-day low: CN¥122

New 90-day low: CN¥132

New 90-day low: CN¥141

New 90-day low: CN¥145

Third quarter earnings released

New 90-day high: CN¥174

Autobio Diagnostics Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: CN¥169

Price target raised to CN¥165

First half earnings released

Autobio Diagnostics Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO

테뉴어

보상